Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 7/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12566957 | 0.81 | POLB (0.49) | POLBNAMPTOPRD1OPRK1GPR119 | |
| SCHEMBL30809160 | 0.80 | POLB (0.42) | POLBNAMPTOPRD1OPRK1MEN1 | |
| SCHEMBL1195130 | 0.80 | AVPR1A (0.47) | POLBMEN1KMT2A | |
| SCHEMBL1195132 | 0.80 | AVPR1A (0.47) | POLBMEN1KMT2A | |
| SCHEMBL4264395 | 0.78 | AVPR1A (0.47) | POLBMEN1KMT2A | |
| SCHEMBL1689606 | 0.78 | AVPR1A (0.47) | POLBMEN1KMT2A | |
| SCHEMBL4282943 | 0.77 | CCR1 (0.42) | POLBNAMPTOPRD1OPRK1MEN1 | |
| SCHEMBL20954719 | 0.77 | CCNC (0.45) | POLBNAMPTOPRD1OPRK1MEN1 | |
| SCHEMBL4294944 | 0.76 | TRPV1 (0.42) | POLBMEN1KMT2AJAK2JAK1 | |
| SCHEMBL4256792 | 0.76 | PROKR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| EP-3480198-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3480198-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-7960401-B2 | Spiropiperidine derivatives for controlling pests | SYNGENTA CROP PROTECTION, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1694677-B1 | SPIROPIPERIDINE DERIVATIVES FOR CONTROLLING PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-20070135408-A1 | Spiropiperidine derivatives for controlling pests | SYNGENTA CROP PROTECTION, INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1694677-A1 | SPIROPIPERIDINE DERIVATIVES FOR CONTROLLING PESTS | Syngenta Participations AG (CH) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005061500-A1 | SPIROPIPERIDINE DERIVATIVES FOR CONTROLLING PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | POLB 2675/4885NAMPT 828/4885OPRD1 718/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | POLB 2991/4885NAMPT 711/4885OPRD1 606/4885 |
| US-20070135408-A1 | Spiropiperidine derivatives for controlling pests | CHRM1, CHRM2, RER1 | POLB 4227/4885NAMPT 3413/4885OPRD1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.